Minomic Archives - We are Minomic

Industry News: MTPConnect’s COVID-19 Impact Report

by Minomic | Jun 17, 2020

Explore the impact of the pandemic lockdown on medtech, biotech and pharma sectors in Australia by downloading MTPConnect’s COVID-19 Impact...

Hot Off the Press – Minomic’s MiCheck^® Prospective Trial Papers Published

by Minomic | May 12, 2020

Minomic International Ltd (Minomic) is pleased to report publication of our back-to-back papers covering the recent MiCheck® prospective trial in the journal Urologic Oncology. The two papers, “A comparison of prostate health index, total PSA, %free PSA, and proPSA in...

Minomic and Sienna enter collaboration agreement to develop pancreatic cancer test

by Minomic | Nov 1, 2019

Pancreatic cancer is the most lethal cancer in humans, with a 5-year survival rate of less than 10%. There are no liquid biopsy assays for the early detection of pancreatic cancer. There is independent evidence that the protein GPC-1 on exosomes is strongly elevated...

Healthcare Leadership Series: Interview with Brad Walsh

by Minomic | May 21, 2019

Click here to watch the interview with Brad Walsh, CEO of Minomic International Ltd. The interview is about: – The perspectives on leadership – Best aspects of being involved in the health sector – Important traits a leader should have in the sector...

Minomic Signs Agreement with US Pathology Laboratory

by Minomic | Feb 14, 2019

Agreement enables early access to the MiCheck® Prostate Cancer Test for US Clinicians & Patients Read Chinese version of the news “Minomic Signs Agreement with US Pathology Laboratory” here February 14, 2019: [Sydney] Minomic International Ltd is...

Minomic secures key patent in the United States and China

by Minomic | Sep 5, 2018

Facebook Twitter Google+ LinkedIn Minomic has received a Notice of Allowance for the company’s patent covering its cell surface antigen for the diagnosis of prostate cancer Sydney, Australia, 5 September 2018: Minomic International Ltd (Minomic), an immuno-oncology...

PUBLICATIONS

Development and evaluation of the MiCheck test for aggressive prostate cancer. Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, et al. Urol Oncol Semin Orig Investig. 2020.

A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population—The MiCheck-01 prospective trial Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, et al. Urol Oncol. 2020.

The Role of Glypican-1 in the Tumour Microenvironment. Lund ME, Campbell DH, Walsh BJ. Adv Exp Med Biol. 2020.

Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. Campbell DH, Lund ME, Nocon AL, Cozzi PJ, Frydenberg M, De Souza P, et al. PLoS One. 2018.

Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker. Levin RA, Lund ME, Truong Q, Wu A, Shore ND, Saltzstein DR, et al. Oncotarget. 2018.

Glypican-1 as a biomarker for prostate cancer: Isolation and characterization. Truong Q, Justiniano IO, Nocon AL, Soon JT, Wissmueller S, Campbell DH, et al. J Cancer. 2016.

PATENTS

Minomic Patent Estate